PDCD1 and metastatic melanoma: Given the fact that anti-PD-1/PD-L1 therapy has now become the backbone of systemic therapy for advanced or metastatic melanoma, a clinically relevant question is whether oncolytic virus therapy offers a benefit following progression on prior anti-PD-1 therapy.